SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ --During the 2026 J.P. Morgan Healthcare Conference (JPM), the 2026 China FIC Innovation & Collaboration Summit was successfully held in San Francisco, th...
The 2026 China FIC Innovation and Collaboration Summit is held on Sunday in San Francisco. The summit, hosted by the Zhongguancun First-in-Class Innovative Drug Global Strategic Development Alliance, ...
From January 12th to 15th, Pacific Time, the 44th J.P. Morgan Healthcare Conference was grandly held in San Francisco, USA. As a "bellwether" in the global biopharmaceutical field, this conf...
TIME: Sunday, Jan 11,2026ADDRESS: Hyatt Regency San Francisco Downtown SOMA Keynote Speech: High-Quality Clinical Trials Underpinning Innovative Drug Developmeng: Development of SGC001, the First-in-W...
The 44th J.P. Morgan Healthcare Conference (JPM 2026), the world's premier healthcare partnership and investment forum, will convene in San Francisco from January 12 to 15, 2026. Beijing Sungen Bi...
On November 3, 2025, Vienna time, Sungen announced the Phase I clinical results of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, at the 31st BIO Europe 2025, h...
Recently, a phase Ib clinical study of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, developed by Sungen, has obtained positive preliminary results. The data s...
On September 24, the "Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs", co-sponsored by a number of industry leading institutions and enterprises such as Hotge...
On April 29th, the Commendation Conference for Model Workers, Advanced Workers and Model collectives in Beijing was grandly held at Beijing Conference Center. Approved by the Beijing Municipal Committ...
On April 28, KPMG China officially released "The 3rd KPMG China's Top 50 Bioinnovation Companies" list. Beijing Sungen Biomedical Technology Co., Ltd. (referred to as "Sungen Biomed...
On March 17, 2025, US time, the world’s first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hot...
At the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), which attracted the attention of global medical industry, Sungen Biomedical's innovative bi-specific antibody SGT003 was unve...
On January 12th, the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), an influential investment seminar, took place in San Francisco. Sungen Biomedical made a notable presentation featu...
Beijing Sungen Biomedical Technology Co., Ltd. (Sungen), which is an innovation-driven, clinical-stage biotechnology company incubated by Beijing Hotgen, is scheduled to attend and present in the 43rd...
On November 16, 2024, the "The first China Pharmaceutical Valley • Future Biological Innovative Drugs Conference" was successfully held in Beijing, which was sponsored by the Management Com...
At 9:00 AM on November 19, the "City Science and Technology Conference / Science and Technology Award Conference" was held in the lecture hall of the Beijing Convention Center. Sponsored by ...
China Food and Drug Network - November 15th to 16th, the first China Pharmaceutical Valley Future Biological Innovative Drug Conference sponsored by the Daxing Biological Pharmaceutical Industry Base ...
On September 27, the award ceremony of EY Fudan Most Potential Enterprise 2024 and the seminar on high-growth enterprises were held in Shanghai.Beijing Sungen Biomedical Technology Co., Ltd. (Sungen B...
Recently, Professor Jie Du from Beijing Anzheng Hospital, Capital Medical University was selected into the list of "Top 2% of Global Scientists with Lifetime Scientific Impact 2024". The lis...
On October 31, 2023, the opening ceremony of the "National Human Brain Health Project" joint laboratory was initiated by Beijing Hotgen Biotech Co., LTD. ( "Hotgen Biotech"), Shenz...
Recently, Beijing Municipal Science and Technology Commission organized experts to conduct on-site evaluation on "Experimental Animal Use License (New)" of Sungen Biomedical Laboratory Anima...
Recently, The X-Gen AI New Drug Discovery and Design Research Center has published a paper titled" Dual Computational and Experimental Strategy to Enhance TSLP Antibody Affinity for Improved Asth...
Recently, the new mechanism of GP73 in liver injury was published in Nature Communications by Professor Sun Zhiwei and Dr. Gao Qi of Sungen Biomedical R&D team，together with Xijing Hospital of Air For...
On January 3, 2024, Taizhou People's Hospital Affiliated to Nanjing Medical University held a conference on "Integrated Development of Hospital and Enterprise - Innovation and Transformation&...
On November 20, 2023, Mr. Lin Changqing, Chairman and president of Beijing Hotgen Biotech Co., Ltd., Professor Du Jie, President of Beijing Antai Institute of Cardiovascular Medicine, and Professor Su...
New quality productivity is a new concept first proposed by JinPing Xi during his investigation in Heilongjiang in September 2023, emphasizing that "integrating scientific and technological innov...
In April 2024, the Beijing Municipal People s Government issued the Decision on the Beijing Municipal Science and Technology Award in 2023. The project of Construction of a transformation sy...
From November 15 to 16, 2024, the highly anticipated "The first China Pharmaceutical Valley • Future Biological Innovative Drugs Conference" was successfully held in Daxing, Beijing. It was...
From November 15th to 16th, "The First China Pharmaceutical Valley · Future Biological Innovative Drug Conference" was held in Beijing. The conference focused on the hot topics of "bio...
Data released by the World Health Organization shows that about 17.5 million people died of cardiovascular diseases worldwide in 2012, accounting for 31% of all deaths worldwide. According to statisti...
On November 22, the "Fourth China Health Industry Development Conference and Golden Cane Award Ceremony" hosted by China Times and China Health Research Institute was held in Beijing. With t...
Today, the development of new drugs is still an "adventure", and the clinical failure rate is very high. According to statistics, new drug development takes an average of 10 years and costs ...
It takes at least 10 years and costs $1 billion to successfully develop a new drug, which is recognized as "double ten laws" in the field of new drug research and development. As new technol...
In recent years, Daxing biomedical industry Base, known as "China's Pharmaceutical Valley", has introduced high-tech enterprises and focused on promoting the integration of artificial in...
The pharmaceutical industry is experiencing a transformative shift, driven by AI-based drug discovery in the realm of biologics. Biologics, complex therapies derived from living organisms, hold immens...
Within the pharmaceutical industry, quality assurance and quality control are terms often used interchangeably because both are integral to quality management and fulfilling customer expectations. The...
In the rapidly evolving world of biotechnology, antibodies have become powerhouse tools in fighting diseases like cancer, autoimmune disorders, and infections. But what sets monoclonal antibodies (mAb...
Bispecific antibodies (BsAbs) are a class of engineered antibodies designed to bind to two distinct antigens simultaneously, setting them apart from monoclonal antibodies in the comparison of monoclon...
In March 2016, the AI program AlphaGo defeated the Korean Go master Lee Sedol, marking a pivotal moment in AI development. This breakthrough not only thrilled the tech world but also ignited hope in t...
MacromoleculesMacromolecules are those with super large molecular weights. The relative molecular mass is usually above 5,000, and can even soar to more than one million, such as proteins, nucleic aci...
Antibody drugs, often referred to as therapeutic antibodies, represent a transformative class of treatments in modern medicine. These specialized proteins are engineered to target specific antigens as...
Artificial intelligence (AI) is revolutionizing pharmaceutical research and development (R&D), offering transformative opportunities to address the industry s challenges of high costs, long timel...
Traditional drug discovery has long been a costly and uncertain process, requiring around $2.6 billion and over ten years to bring a drug to market, with a success rate of less than 10%. However, arti...
A groundbreaking study by Canada's National Research Council highlights the impressive capabilities of AI-enhanced molecular docking, which outperforms traditional methods in predicting the three-...
Antibody StructureImmunoglobulins (Ig) or antibodies are important components of the immune system. They can specifically bind antigens through antigen-binding fragment(Fab) sites and activate other c...
Macromolecular drugs (macromolecules), also known as biologics, are medicines used for the prevention, treatment and diagnosis of human diseases, which are prepared by applying common or biological ma...
Based on structure and functional mechanisms, antibody therapies can be divided into three main forms: monospecific antibodies, bispecific antibodies, and antibodies conjugated with payloads(such as d...
In the past few decades, antibody drugs have thoroughly revolutionized the pharmaceutical industry and saved countless lives. Since the introduction of the first approved monoclonal antibody drug, Ort...
CMC (Chemistry, Manufacturing, and Controls) process is a critical part of the development and production of biopharmaceuticals, mainly involving aspects related to the chemistry, manufacturing, and q...
